BEFAST Study, [68Ga]Ga-FAPI Total Body PET/CT for Better and Faster Imaging in Cancer
Recruiting
Phase 2
Interventional Study
Pancreatic Cancer, Adult
Gastroesophageal Cancer (GC)
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Diagnostic
- Participants needed
- 90 (estimated)
- Sponsor
- Barbara Malene Fischer · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this clinical trial is to learn if \[68Ga\]Ga-FAPI-46 Total Body PET/CT can diagnose patients suffering from gastroesophageal cancer and pancreatic cancer. The investigators hope that \[68Ga\]Ga-FAPI-46 Total Body PET/CT can improve staging and treatment evaluation for these patient groups.
The main questions the trial aims to answer are:
* Is \[68Ga\]Ga-FAPI-46 Total Body PET/CT bet…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion criteria for group A
1. Male or female, over 18 years old
2. Patients with suspected pancreatic cancer based on morphological findings on standard imaging
3. CT or MRI or \[18F\]FDG PET/CT evaluated on MDT with no initial sign of distant metastases
4. Subjects must have been considered su…
Contacts